Views: 1,509 | Downloads:
27
| Responses: 0
| XML | Respond to this article | Alert & updates | Request permissions | Email to a friend |
Original ArticleOpen Access
Effect of Acarbose in Treatment of Type II Diabetes Mellitus: A. Double-blind, Crossover, Placebo-controlled Trial
Soonthompun S 
,
Rattarasam C ,
Thamprasit A ,
Leetanapom K
,
Rattarasam C ,
Thamprasit A ,
Leetanapom K This study evaluated the efficacy of acarbose in improvement of metabolic control in
patients with fairly, well controlled non-insulin-dependent diabetes mellitus (NIDDM). Fifteen
patients with mean age and duration of diabetes of 57.5±2.6 (SE) and 7.5±1.5 years, respectively
were recruited and completed our study protocol. This study was a double-blind, crossover,
placebo-controlled design consisting of two twelve-week treatments of acarbose and placebo
separated by an eight-week washout period. Acarbose was effective in lowering of !-hour and
2-hour postprandial plasma glucose from 251.7±10.7 and 205.3±9.1 mg/dl to 197.4±7.0 (p=
0.001) and 181.5±8.5 mg/dl (p=0.03), respectively. Fasting plasma glucose was slightly
decreased but without significant change, from 150.8±7.3 to 140.8±6.1 mg/dl (p=0.07). Overall
glycemic control tended to improve during the study period as indicated by the falling of
HbA1c levels from 7.7±0.4 to 7.0±0.2 per cent (p=0.05). Serum C-peptide both fasting and postprandial
as well as serum lipids were not affected by acarbose. Almost half of the patients treated
with acarbose had mild and tolerable gastrointestinal adverse effects. In conclusion, acarbose,
as combined therapy with other oral hypoglycemic agents, was effective in improvement of
glycemic control particularly postprandial hyperglycemia in fairly, well controlled NIDDM
patients with mild and acceptable adverse effects.
patients with fairly, well controlled non-insulin-dependent diabetes mellitus (NIDDM). Fifteen
patients with mean age and duration of diabetes of 57.5±2.6 (SE) and 7.5±1.5 years, respectively
were recruited and completed our study protocol. This study was a double-blind, crossover,
placebo-controlled design consisting of two twelve-week treatments of acarbose and placebo
separated by an eight-week washout period. Acarbose was effective in lowering of !-hour and
2-hour postprandial plasma glucose from 251.7±10.7 and 205.3±9.1 mg/dl to 197.4±7.0 (p=
0.001) and 181.5±8.5 mg/dl (p=0.03), respectively. Fasting plasma glucose was slightly
decreased but without significant change, from 150.8±7.3 to 140.8±6.1 mg/dl (p=0.07). Overall
glycemic control tended to improve during the study period as indicated by the falling of
HbA1c levels from 7.7±0.4 to 7.0±0.2 per cent (p=0.05). Serum C-peptide both fasting and postprandial
as well as serum lipids were not affected by acarbose. Almost half of the patients treated
with acarbose had mild and tolerable gastrointestinal adverse effects. In conclusion, acarbose,
as combined therapy with other oral hypoglycemic agents, was effective in improvement of
glycemic control particularly postprandial hyperglycemia in fairly, well controlled NIDDM
patients with mild and acceptable adverse effects.
Download:
PDF